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Background: Anthracycline-induced cardiotoxicity typically presents as congestive heart failure (CHF). As
immuno-inﬂammatory activation and apoptosis are important mechanisms in the process of heart failure, the
use of biomarkers that could detect cardiovascular toxicity before the clinical presentation is of great importance.
We studiedwhether sTNF-a, sTNF-RI, sTNF-RII, Fas/FasLigand system andNT-proBNP associatewith early cardiac
dysfunction in patients receiving cardiotoxic drugs.
Methods: Two groups of breast cancer patients—group A with metastatic disease under chemotherapy with
epirubicin and group B with no residual disease under a less cardiotoxic regimen—as well as healthy women
were included in this prosprective study. NT-proBNP, sTNF-a, sTNF-RI, sTNF-RII, sFas, sFas-Ligand and left ventric-
ular ejection fraction (LVEF) were determined in all patients before and after the completion of chemotherapy.
Results: In Group A, an increase in sFas levels (p b 0.001), a decrease in the sFasL levels (p=0.010), anNT-proBNP
increase (p b0.001) and a signiﬁcant reduction of LVEF (p b 0.001) was recorded post-chemotherapy. The de-
crease in LVEF correlated signiﬁcantly with the increase in sFas, the decrease in sFasL and the rise in NT-
proBNP levels. In Group B, TNF-RI levels were higher (p = 0.024) and mean sFas-L levels lower (p = 0.021)
post chemotherapy with no LVEF drop. Two of group A (7.6%) patients developed symptomatic CHF 12 and 14
months respectively after the end of chemotherapy.
Conclusion: SFas, sFas-L and NT-proBNP correlate with reductions in LVEF and could be used as sensitive bio-
chemical indices for the detection of asymptomatic left ventricular dysfunction in cancer patients under
cardiotoxic chemotherapy.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Anthracyclines have been associatedwith cardiomyopathy since their
introduction in the late 1960s [1]. Anthracycline cardiomyopathy has
been described as having three clinical presentations: acute, subacute
and late. The acute toxicity is generally minor and reversible ranging
from asymptomatic electocardiographic (ECG) changes to rare cases of
severe acute myopericarditis [2]. Subacute and late toxicity secondary
to anthracycline use typically presents with congestive heart failure30 2109493373.
inis).
eliability and freedom from bias
nd Ltd. This is an open access article un(CHF). The classic subacute presentation usually appears from 0 to
231 days with a peak onset of symptoms at 3 months from the last
dose [3] whereas the late presentation has been described to occur 5 or
more years after the completion of chemotherapy [4]. Asymptomatic car-
diac dysfunction is considered to precede symptoms of CHF and consists
mainly of systolic rather than diastolic left ventricular dysfunction [5].
Amongst the two widely used anthracyclines, epirubicin is consid-
ered to be less cardiotoxic thandoxorubicin, and its related cardiotoxicity
is closely coupled to the cumulative dose, inducing a life-threatening,
slowly progressive deterioration of cardiac function [6]. It has been stated
that the risk of cardiotoxicity is less than 1% at doses below 550 mg/m2
but increases up to 4% at 900 mg/m2 and 15% at 1000 mg/m2 [7].
Currently, the main non-invasive diagnostic tool for the detection of
anthracycline-related cardiotoxicity is the estimation of left ventricular
ejection fraction (LVEF), by means of radionuclide ventriculography order the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
86 A. Kouloubinis et al. / IJC Heart & Vasculature 6 (2015) 85–902D-echocardiogram. Radionuclide ventriculography is a well validated,
established and widely used method for the evaluation of the LVEF that
presents high reproductibility and low intraindividual variabilility [8]. In
that respect, the endomyocardial biopsy is considered to be themost sen-
sitive and speciﬁc method of evaluating anthracycline cardiomyopathy
with considerable limitations however due to its invasive nature and
the potential of adverse events [9]. Therefore, the identiﬁcation of newdi-
agnostic indices, such as biomarkers, that could non-invasively detect,
well before the onset of clinical symptoms, cardiac dysfunction and car-
diovascular toxicity, would be of vital importance for the current clinical
practice.
Immuno-inﬂammatory activation and cardiomyocyte apoptosis
have been demonstrated as important pathophysiological mechanisms
in the process of heart failure due to any cause but anthracycline-
exposure [10]. Circulating plasma levels of the tumor necrosis factor
(TNF)-superfamily [TNF-α, TNF Receptors 1 and 2 (TNF-RI, TNF-RII)]
and of the apoptosis inhibitor sFas are elevated in heart failure patients
and correlate with New York Heart Association (NYHA) class of severity
[11,12] and prognosis [13,14]. Finally, the natriuretic peptide NT-
proBNP is a well established biomarker of enhancedwall stress and car-
diac diastolic and systolic dysfunction, and an independent and strong
predictor of heart failure progression [15].
In thepresent study,we prospectively evaluated the cardiac function
and the immuno-inﬂammatory status of patients with breast cancer
(metastatic or not) that received either an epirubicin-based cardiotoxic
chemotherapy or a non cardiotoxic regimen. The aimof the studywas to
assess whether the pro-inﬂammatory cytokines, the soluble apoptotic
Fas/FasLigand system and more established markers of left ventricular
dysfunction such as NT-proBNP and LVEF associate with early asymp-
tomatic cardiac dysfunction in patients receiving cardiotoxic drugs.2. Methods
2.1. Patient population
The study population consisted of forty consecutive female patients
with histologically conﬁrmed breast cancer that were included in the
study between 08/2001 and 12/2002. All patients were consented and
studied in the oncology department of ‘Metaxa Oncology Hospital’ ac-
cording to the principles outlined in the Declaration of Helsinki and
with the ethical approval of the institution.
Patients were included in the study only if they fulﬁlled the follow-
ing criteria: i) absence of any established preexisting heart disease
(such as coronary artery disease, arrhythmias, valve disease, hyperten-
sive heart disease and congestive heart failure) on the basis of medical
history, clinical examination and diagnostic evaluation, ii) LVEF values
above 50% determined by radionuclide ventriculography iii) ECOG
(Eastern Oncology Cooperative Group) Performance Status 0,1 and 2,
iv) normal renal (serum creatinine b 1.3 mg/dL) and normal or slightly
deranged hepatic function (aspartate aminotransferase b80 IU/l or ala-
nine aminotransferase b80 IU/l) and, v) no history of other malignant
disease. Exclusion criteria were: administration of chemotherapy and/
or hormonal therapy or local radiotherapy 6 months prior to the study.
Tumor-Node-Metastasis (TNM) classiﬁcation was used in order to
determine the stage of the disease. Either total or partial mastectomy
with axillary lymphadenectomy was the surgical procedure of choice
for all patients. Computed tomography scan was performed in order
to identify presence of distal (liver, lung, brain and lymph node)metas-
tases whereas bone metastases were diagnosed by means of X-ray and
bone scintigraphy.
Patients were split into two groups (group A and group B) according
to the presence of metastatic or advanced disease. Group A patients
were those with advanced or metastatic disease whereas group B
were patients with no residual disease post-surgery. Group C is an age
matched group of healthy women.2.2. Chemotherapy
GroupA patients received amore cardiotoxic chemotherapeutic reg-
imen that was consisted of 6 cycles of epirubicin 80–90 mg/m2 given as
bolus intravenous infusion and paclitaxel 150 mg/m2 given as an intra-
venous 3-hourly infusion, on day one. The cycles were repeated every 3
weeks. No patient had previously received any anthracycline-based
chemotherapeutic regimen. Left-sided chest wall irradiation was the
adjuvant treatment of choice for two (2) patients and right-sided
chest wall irradiation for three (3), at least six months prior to their en-
rolment in the study.
Group B patients received a less cardiotoxic chemotherapy regimen
which consisted of docetaxel 75–85 mg/m2 as well as mitoxantrone
7.5–8.5 mg/m2 both intravenously as a 1-hour infusion on day one.
The cycleswere repeated every 3weekswhile the duration of treatment
was six cycles.
2.3. Plasma soluble inﬂammatory and apoptotic markers
Peripheral blood samples were collected before the onset and after
the end of treatment, in 10 ml EDTA (2-natrium-ethylenediamine
tetra-acetic acid) containing disposable tubes. The sampleswere centri-
fuged at 3000 rpm for 7min, and serumwas separated and immediately
stored at (−70 °C) until assay. Plasma levels of NT-proBNP were mea-
sured before and after chemotherapy bymeans of an enzyme immuno-
assay in fmols/ml (BIOMEDICA AUSTRIA), whereas, soluble (s) TNF-a,
sTNF receptors I and II, as well as, sFas and sFas ligand, were assayed
in duplicate by using commercially available enzyme-linked immuno-
sorbent assay kits (R&D Systems, Minneapolis, Minnesota) according
to the manufacturer's descriptions.
2.4. Radionuclide ventriculography
Radionuclide ventriculography was used to determine LVEF. There-
fore, 400 MBq of Tc-99 m-labeled autologous RBCs were injected and
acquisition was performed in 6 min with a large-ﬁeld-of-view gamma
camera with a low energy, all-purpose, parallel-hole collimator.
Abnormal values were considered LVEF values below 50%. Signiﬁ-
cant cardiac toxicity was determined as LVEF decline greater than 10%
from baseline level. LVEF was assessed in Group A and B patients before
the onset andwithin oneweek after the end of chemotherapy. All group
A and B patients had normal cardiac function before induction of che-
motherapy. Control group C had LVEF levels above 50% and therefore
normal ventricular systolic function.
2.5. Cardiac evaluation
Group A and B patients were examined physically before each cycle
and were followed up every three months after the end of the chemo-
therapy. In addition, they were evaluated with a standard 12 lead ECG
every three chemotherapy cycles. Bazett's formula (QTc = QT/√RR)
was used to correct QT time for heart rate (QTc) which was considered
prolonged if more than 440 ms.
3. Statistical analysis
Kolmogorov–Smirnov test was used to assess normal distribution.
Values are presented as mean (standard error) for normally distributed
continuous variables, as median (interquartile range) for skewed vari-
ables and as frequency (%) for categorical variables.
For independent group comparisons one-way ANOVA (post hoc
Sidak test) or Kruskal Wallis test (post hoc Dunn's test) were used for
normally and not normally distributed variables respectively. Correla-
tions between variableswere tested by Pearson's or Spearman's correla-
tion coefﬁcients as appropriate. For pair wise comparisons (before and
after treatment) the paired t-test or the Wilcoxon signed-rank test
Table 1
Baseline characteristics of the 3 groups.
Group A Group B Group C
N 26 14 20
Age (years) 54.5 ± 10.2 56.5 ± 11.6 56.5 ± 16
Clinical status
(stage of disease)
Breast cancer, metastatic
stages IIIA/IIIB/IV
Breast cancer
No residual disease after surgery
stages IIA/IIB/IIIA
Healthy
Anti-cancer
treatment
Epirubicin/paclitaxel Docetaxel/mitoxantrone No treatment
Baseline LVEF N50% N50% N50%
Cardiac evaluation Clinical examination before each cycle and
every three months after the end of treatment.
ECG every three chemotherapy cycle
Clinical examination before each cycle and
every three months after the end of treatment.
ECG every three chemotherapy cycle
No evaluation
Follow-up
(median)
62 months
(range: 52–78)
62 months
(range: 52–78)
No follow-up
Results are presented as means ± SD or percentages. LVEF: left ventricular ejection fraction, ECG: electrocardiogram
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contingency chi-square test or Fisher exact test.
A p-value b0.05 (2-tailed) was considered statistically signiﬁcant.
Statistical analysis was performed using SPSS software, version 15
(SPSS Inc, Chicago, Illinois).
4. Results
4.1. General demographics and ECG parameters
The study population consisted of 40 breast cancer patients and 20
age-matched female controls. In group A,metastatic sites, prior to treat-
ment, involved the liver (n= 7), the lungs (n= 4), the bones (n= 2),
and lymph nodes (n = 1). Mean age (SD) of group A (n = 26) was
54.4 ± 10.2, of group B (n= 14) 53.3 ± 11.7 and of group C (n= 20)
54.3 ± 16.6 (p = 0.803). Table 1 summarizes all the baseline
characteristics.
During the study period no ECG changes were demonstrated in
group A and B patients. As regards to QTc time no signiﬁcant prolonga-
tion was recorded in the above groups.
4.2. Baseline (pro-chemotherapy) immuno-inﬂammatory markers and NT
pro BNP across Group A and B patients and healthy controls (group C)
There are signiﬁcantly increased levels of sFas, TNFa and TNFR1 and a
trend for increased levels of TNFR2 amongst groupA patientswhen com-
pared to healthy controls (Table 2). No difference is observed across the
three groups (A, B and C) with regards to NT-pro BNP levels (Table 2).
4.3. Immuno-inﬂammatory markers, NT pro BNP and LVEF pre- and post-
chemotherapy in Groups A and B
In Group A patients, there was a signiﬁcant rise in the mean sFas
levels (p b 0.001) and a signiﬁcant decrease in the sFasL levels (p =
0.010) post-chemotherapy. There was no signiﬁcant change in theTable 2
Baseline immuno-inﬂammatory parameters and serum NT-proBNP levels in Group A and B pa
Group A Group B
sFas (ng/ml) 192.9 (134.0 to 413.7)a 152.9 (10
sFas-L (ng/ml) 75.1 (43.1 to 126.3) 79.0 (49.
TNF-a (ng/ml) 2.0 (1.4 to 3.5)a 1.8 (1.0 t
TNF-RI (ng/ml) 144.3 (124.9 to 189.8)a 110.8 (90
TNF-RII (ng/ml) 238.0 (197.3 to 346.4) 189.1 (16
BNP (fmol/ml) 158.0 ± 8.4 189.0 ±
Results are presented as means ± SE and median (IQR).
BNP: brain natriuritic peptide, TNF: tumor necrosis factor, R: receptor, IQR: interquartile range
a Post hoc p b 0.05 between groups as calculated using Dunn's test.serum values of sTNF-a, sTNF-RI and sTNF-RII pre and post treatment
(Table 3).
Plasma levels of NT-proBNP increased signiﬁcantly after chemother-
apy (283.3± 27.2 vs. 158.0± 8.4, post- and pre chemo respectively, p b
0.001) (Table 3). The LVEFwas signiﬁcantly reduced post chemotherapy
(61.6 ± 1.2 vs. 58.0 ± 1.1, p b 0.001). The statistical signiﬁcance of the
above comparisons remained after Bonferroni correction for multiple
comparisons. Three patients (11.5%) had signiﬁcant LVEF drop
(i.e N10%) post chemotherapy.
In Group B, TNF-RI levels were signiﬁcantly higher and mean sFas-L
levels signiﬁcantly lower post chemotherapy (Table 3). The increased
sFas levels post chemotherapy lost statistical signiﬁcance when
performing Bonferroni correction (p= 0.028 × 2 = 0.056). There was
no signiﬁcant difference amongst the rest biochemical and apoptotic
markers including NT-proBNP. The mildly reduced LVEF post chemo-
therapy also lost statistical signiﬁcance after Bonferroni correction for
multiple comparisons (p=0.033×2=0.066). No patients had a signif-
icant LVEF drop post chemotherapy.
4.4. Correlations of LVEF reduction with other parameter changes pre- and
post-chemotherapy
In group A the decrease in LVEF correlated signiﬁcantly with the in-
crease in sFas the decrease in sFasL and the rise in NT-proBNP levels. In
patients treated with the “low risk” cardiotoxic regimen (Group B) no
signiﬁcant LVEF alterations were recorded after chemotherapy and no
association between the LVEF and changes in sFas, sFasL, TNF-α or NT-
proBNP levels was demonstrated (Table 4).
4.5. Follow-up
4.5.1. Group A
Two of the 26 (7.6%) of group A patients developed symptomatic
congestive heart failure (CHF) 12 and 14 months respectively after the
end of chemotherapy. Both patients had to be admitted in hospital for
5 and 7 days respectively. The ﬁrst patient was found to have an LVEFtients and healthy controls (Group C).
Group C P-value
2.5 to 214.0) 111.3 (92.1 to 131.4)a b0.001
9 to 94.6) 66.1 (50.9 to 77.9) 0.601
o 2.6) 1.4 (0.7 to 2)a 0.021
.8 to 151.3) 103.9 (78.5 to 119.7)a b0.001
6.3 to 252.4) 196.8 (187.8 to 214.6) 0.015
18.2 150.4 ± 15.9 0.163
.
Table 3
Serum inﬂammatory, antiapoptotic indices and BNP levels as well as estimated LVEF prior and after chemotherapy in Group A (cardiotoxic chemo) and Group B (non cardiotoxic chemo)
patients.
Group A Group B
before Tx after Tx P-value before Tx after Tx P-value
sFas (ng/ml) 308.8 ± 65.1 517.8 ± 91.0 b0.001 171.6 ± 22.5 229.5 ± 25.8 0.028
sFas-L (ng/ml) 86.6 ± 12.6 47.9 ± 8.4 0.010 77.1 ± 33.1 70.0 ± 32.4 0.021
TNF-a (ng/ml) 3.2 ± 0.7 3.6 ± 0.7 0.195 1.8 (1.0 to 2.6) 1.8 (1.3 to 2.6) 0.551
TNF-RI (ng/ml) 165.1 ± 12.6 166.7 ± 10.9 0.883 123.7 ± 11.7 149.5 ± 11.0 0.024
TNF-RII (ng/ml) 270.8 ± 19.2 275 ± 16.1 0.793 219.4 ± 23.0 237.9 ± 16.1 0.444
NT-proBNP (fmol/ml) 158.0 ± 8.4 283.3 ± 27.2 b0.001 189.0 ± 18.2 194.9 ± 19.6 0.529
LVEF 61.6 ± 1.2 58.0 ± 1.1 b0.001 61.7 ± 1.7 59.9 ± 2.0 0.033
Results are presented as means ± SE and median (IQR).
BNP: brain natriuretic peptide, EF: ejection factor, Tx: chemotherapy, TNF: tumor necrosis factor, R: receptor, IQR: interquartile range.
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previously from 65% before chemotherapy to 47% after chemotherapy.
An LVEF decline was also shown in the second patient from 70%
prior to chemotherapy to 59% after chemotherapy and to 45% while
hospitalization. The levels of sFas before and after the completion of
chemotherapy increased from 2.32 to 6.7 ng/ml in the ﬁrst patient
and from 17.47 to 22.59 ng/ml in the second patient whereas NT-pro
BNP values rose from 152 to 492 fmol/ml and from 153 to 571
fmol/ml respectively.
At 62months of follow up 2 patients (7.6%) remained free of disease
after the initial chemotherapy, 9 patients (34.6%) were still being treat-
ed with second and third line chemotherapy, 13 patients died due to
metastatic disease and2 patientswere lost from follow-up.With the ex-
ception of the 2 abovementioned patients thatwere hospitalized for HF
and the 2 who were lost in follow-up, the rest of the patients were
asymptomatic with respect to symptoms related to cardiac dysfunction.
4.5.2. Group B
No patient developed symptoms of congestive heart failure during
the follow-up period. Six patients totally remained free of diseasewhere-
as other six experienced disease recurrence andweremanagedwith sec-
ond line chemotherapeutic regimens and 2 were lost from follow-up.
5. Discussion
The present study is the ﬁrst to show a signiﬁcant increase in the
anti-apoptotic receptor sFas and decrease in the apoptosis inducer
sFasL levels, after anthracycline epirubicin chemotherapy in patients
with advanced or metastatic breast cancer. Both indices were associated
with a signiﬁcant decrease in LVEF. The cardiotoxicity of epirubicin was
also expressed by a signiﬁcant increase in NT proBNP levels after
epirubicin chemotherapy in the same group of advanced breast cancer
patients. These increased BNP levels associated signiﬁcantly with a
decrease in the radionuclide ventriculography derived LVEF post
chemotherapy.
The concurrent increase of sFas and NT-proBNP levels alongside the
LVEF decline just one week after the discontinuation of the potentiallyTable 4
Correlations between LVEF change and differences (d) (post chemo− pre chemo) in various p
NT-proBNP sFASd FAS-Ld
Group A
LVEFd r=−0.786 r=−0.438 rho = 0.549
p b 0.001 p= 0.025 p= 0.004
Group B
LVEFd r= 0.107 r=−0.277 r= 0.313
p= 0.716 p= 0.338 p= 0.276
BNP: brain natriuretic peptide, EF: ejection factor, TNF: tumor necrosis factor, R: receptor, (i.e. IQR
r= Pearson's correlation.
rho = Spearman's correlation.cardiotoxic regimen preceded considerably the clinical manifestation
of left ventricular dysfunction in Group A. In the clinical setting, al-
though the initial LVEF dropped signiﬁcantly in 11.5% of group A pa-
tients after chemotherapy no symptoms of cardiac dysfunction were
reported until several months after the completion of chemotherapy
when the cardiotoxicity of epirubicin was expressed as heart failure in
7.6% of group A patients. All the above ﬁndings and associations applied
only for the category of patients that received the more cardiotoxic re-
gime containing epirubicin but not for any of the patients that were
treated with the less cardiotoxic one.
The anthracycline cardiotoxicity is cumulative, dose-related and at
sufﬁciently high dosages can result in congestive heart failure (CHF)
and left ventricular (LV) dysfunction. Ιt represents a long term
cardiotoxicity—type I cardiotoxicity—induced by cardiomyocyte death
either through necrosis or apoptosis [16]. The mechanism of cell death
varies with anthracycline concentration with apoptosis occurring at
lower and necrosis at higher concentrations [17]. Amongst the several
and different mechanisms that have been proposed to explain the
toxic effects of anthracyclines on cardiac myocytes, the most important
of them are: nuclear DNA damage [18], mitochondrial DNA mutations
[19], and changes in phospholipid content and calcium availability
[20]. The toxicity that anthracyclines—and mainly doxorubicin—exhibit
in cardiomyocytes is attributed to free radical formation caused by their
metabolism [21]. The reactive oxygen species that are produced by
doxorubicin metabolism in cardiomyocytes subsequently cause cell
death through apoptotic pathways [22,23]
Oxidative stress can also occur via induction of nitric oxide synthase,
leading to nitric oxide and peroxynitrite formation [24]. This mecha-
nism has been linked to nitration and inactivation of key enzymes in
the heart including myoﬁbrillar creatine kinase [25]. In the heart, like
other tissue, anthracyclines intercalate into nucleic acids, causing sup-
pression of DNA, RNA and protein synthesis [26]. Impaired synthesis
of myoﬁlament proteins, [27], leads to a net negative balance of sarco-
meric proteins, a condition we have termed ‘cardiac sarcopenia’. In ad-
dition anthracyclines induce changes in adrenergic function and
adenylate cyclase [28,29], as well as abnormalities in Ca2+ handling
[30], all critical for the dynamic regulation of cardiac function.arameters.
TNF-ad TNFR1d TNFR2d
r=−0.284 r=−0.018 r= 0.125
p= 0.160 p= 0.931 p= 0.544
rho =−0.132 r=−0.021 r=−0.189
p= 0.653 p= 0.944 p= 0.517
: interquartile range).
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cardiac rhythm and conduction, the combination of anthracycline
with paclitaxel increases the risk of cardiac dysfunction especially
when epirubicin's cumulative dose exceeds 550 mg/m2 [7,31].
The combination of docetaxel and mitoxantrone has not been asso-
ciated with deterioration of cardiac function, even in cumulative doses
of 100 mg/m2 and 22 mg/m2, respectively [32]. The concurrent admin-
istration of the two drugs seems to be safe for patients with normal LV
function [32], although there have been some studies showing that
mitoxantronemay cause cardiac toxic events in a dose dependentman-
ner [33]. Our study did not demonstrate any evidence of cardiotoxicity
related to the treatment with mitoxantrone and the combination with
docetaxel did not increase that risk.
It has been shown that apoptosis and immune activation are impor-
tant determinants of both pathogenesis and evolution of heart failure
[34,35]. Elevated plasma sFas levels have been demonstrated in chronic
heart failure and have also been reported to increasewith disease sever-
ity and prognosis [12], thus highlighting the pathophysiological role of
sFaswhich has also been implicated in dilated (ischemic and inﬂamma-
tory) cardiomyopathies [36,37]. A recent study has shown that sFas is an
independent risk predictor in advancedHFpatients, correlateswith BNP
and can improve prediction beyond the BNP [14]. In the present study
we report an increase in sFas and NT-proBNP levels post chemotherapy
in the group of patients who received themore cardiotoxic regimen, de-
spite them not manifesting any heart failure symptoms at that point of
time. The higher sFas plasma levels observed in group A patients after
chemotherapy, could be indicative of greater tissue and/or cellular inju-
ry caused by the ‘high risk’ cardiotoxic regimen, compared to the ‘low
risk’ one. Increased wall stress in the affected heart ventricles can
cause raised BNP production by the myocytes and probably stretch-
induced expression of Fas protein [38]. In our previous study we dem-
onstrated NT-pro BNP elevation after cardiotoxic chemotherapy with
epirubicin in female patients with advanced breast cancer [39].
With regards to the two patients that later developed CHF after re-
ceiving epirubicin, they both exhibited LVEF decrease associated with
sFas and NT-proBNP rise after chemotherapy. The increased immuno-
inﬂammatory markers in group A at baseline conﬁrm the well known
effects of metastatic/advanced cancer on the immune system [40,41].
However this baseline difference did not affect our results as we were
focusing on post chemo differences rather than absolute values.
Our study is the ﬁrst one to demonstrate a signiﬁcant change in the
apoptotic markers sFas and sFas-L after the administration of
epirubicin-based cardiotoxic chemotherapy. Moreover the association
between the change of sFas and sFas-L and the LVEF decline is a novel
ﬁnding. A limitation of our study is the small number of patients
which reﬂects the difﬁculty in consenting patientswith cancer to partic-
ipate in a research project that involves further blood tests and diagnos-
tic procedures.
Given that all three, the anti-apoptotic marker sFas, the apoptosis in-
ducer sFas-L and the wall stress indicator NT-proBNP, correlate with re-
ductions in LVEF, the above biochemical indices could be used in the
near future either independently or even synergistically for the detection
of early stages of LV (diastolic and/or systolic) dysfunction. Future studies
might disclose additive diagnostic and prognostic value of sFas, sFas-L,
and NT-proBNP for the detection of early asymptomatic LV dysfunction
in this sensitive category of cancer patients. Establishing reliable and sen-
sitive diagnostic indices for the early detection and treatment of the
asymptomatic LV dysfunction in this group of patients is of great impor-
tance, as it facilitates adjustment of chemotherapy, reduces the risk from
cardiac disease and limits the comorbidities that could aggravate the al-
ready compromised quality of life of the cancer survivors.
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